The GE Healthcare will today, Friday, August 4 unveil the latest technology in supplemental screening for breast cancer patients in Nigeria.
According to the firm, its latest comprehensive portfolio of breast imaging technologies called Invenia ABUS transforms breast care from reactive to proactive, helping to detect breast cancers in dense tissue.
The presentation is scheduled to hold at Alpha Pharmacy while launching will take place at Care Organization Public Enlightenment (C.O.P.E), a non-governmental, non-profit organization established in 1995 as breast cancer resource service provider for students, women, breast cancer survivours and care givers. Both venues are on Adeniyi Jones Avenue, Ikeja, Lagos. Nigeria’s leading digital retail Bank, Polaris Bank will also present a goodwill message at the presentation and unveiling.
The Invenia ABUS, a first of its kind in Nigeria, will be formally presented to C.O.PE upon its final acquisition by the foremost breast cancer- focused NGO.
Approximately 40% of women have dense breasts, one of the strongest common risk factors for developing breast cancer. Clinical evidence is growing about the effectiveness of ultrasound for finding small, node-negative, invasive cancers missed by mammography. Invenia ABUS supplemental imaging is designed for the screening environment, specifically for dense breast imaging.
Some of the special features and benefits of the Invenia ABUS are as highlighted below:
CARE FOR DENSE BREASTS
Personalized breast care with Invenia ABUS for early detection, confident diagnosis, and treatment along the breast care pathway.
Dense breast tissue and cancer appear white on a mammogram, potentially camouflaging small cancers. Invenia ABUS, is specifically designed to help clinicians find cancers that may be hidden on mammography.
Recall that the Founder/CEO of COPE, Ebunola Anozie had earlier in an exclusive interview with NewsClick Nigeria said breast cancer is most often found in women, but men can get it too.
SCREENING
The power of early cancer detection.
Supplemental screening with Invenia ABUS transforms breast care from reactive to proactive. When used in addition to mammography, Invenia ABUS can improve breast cancer detection by 35.7 percent over mammography alone. Women whose breast cancer is detected at an early stage have a 90% or higher survival rate.
DIAGNOSIS & STAGING
Lesion characterization for confident staging in dense breasts
Invenia ABUS uses the latest ultrasound innovations and AI based solutions to help improve precise diagnosis and elevate clinical confidence.
TREATMENT
Smart surgical planning
Invenia ABUS provides a full view of the breast, depicting the extent of the lesion, multiplicity and potential stromal involvement, helping to achieve a better surgical approach.
FOLLOW UP
Easy monitoring of treatment progress
Invenia ABUS uses patient friendly imaging to help monitor treatment progress with the goal of avoiding complications and risk of cancer recurrence. Features such as auto prior function provide a standardized comparison with previous findings.
